2023
Beyond Loss of Kidney Function: Patient Care in Autosomal Dominant Polycystic Kidney Disease
Hogan M, Simmons K, Ullman L, Gondal M, Dahl N. Beyond Loss of Kidney Function: Patient Care in Autosomal Dominant Polycystic Kidney Disease. Kidney360 2023, 4: 1806-1815. PMID: 38010035, PMCID: PMC10758524, DOI: 10.34067/kid.0000000000000296.Peer-Reviewed Original ResearchConceptsAutosomal dominant polycystic kidney diseaseDominant polycystic kidney diseasePolycystic kidney diseaseKidney diseaseKidney Disease Improving Global Outcomes guidelinesGlobal Outcomes (KDIGO) guidelinesInitiation of RRTSuccessful kidney transplantEvidence-based guidelinesCurrent clinical practiceKidney stone managementMajor morbidityCardiac manifestationsKidney transplantOutcomes guidelinesKidney functionDepression screeningDisease benefitPancreatic cystsSpecialized careRoutine managementClinical practicePatient careStone managementDisease aspectsRisk Factors for Common Kidney Stones Are Correlated with Kidney Function Independent of Stone Composition
Simmons K, Nair H, Phadke M, Motamedinia P, Singh D, Montgomery T, Dahl N. Risk Factors for Common Kidney Stones Are Correlated with Kidney Function Independent of Stone Composition. American Journal Of Nephrology 2023, 54: 329-336. PMID: 37253348, DOI: 10.1159/000531046.Peer-Reviewed Original ResearchConceptsEstimate glomerular filtration rateLower estimate glomerular filtration rateRisk factorsUrine chemistryUnivariable analysisMultivariable analysisStone compositionKidney stonesKidney stone risk factorsCommon stone compositionUrine risk factorsRetrospective cohort studyStone analysisStone risk factorsGlomerular filtration rateLow urine pHBody mass indexKidney stone patientsCalcium-containing stonesUric acid stonesStone composition dataUrine oxalateRenal functionCohort studyKidney functionKidney cysts in patients with HOGA1 variants.
Patel D, Page N, Dahl N. Kidney cysts in patients with HOGA1 variants. Clinical Nephrology 2023, 99: 260-264. PMID: 36928260, DOI: 10.5414/cn110939.Peer-Reviewed Original ResearchPharmacologic Management of Autosomal Dominant Polycystic Kidney Disease
Ackley W, Dahl N, Park M. Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease. Advances In Kidney Disease And Health 2023, 30: 228-235. PMID: 37088525, DOI: 10.1053/j.akdh.2023.02.002.Peer-Reviewed Original ResearchConceptsAutosomal dominant polycystic kidney diseaseEnd-stage kidney diseaseKidney diseaseDominant polycystic kidney diseasePolycystic kidney diseaseRapid progressionMechanism-specific treatmentsChronic kidney diseaseFourth leading causeTreatment of patientsPharmacologic managementLeading causeKidney disordersFDA approvalDiseaseTolvaptanProgressionTreatmentRiskMorbidityPatientsPathogenesisTherapy
2022
Perspectives on Drug Development in Early ADPKD
Mekahli D, Womack H, Dahl NK. Perspectives on Drug Development in Early ADPKD. Clinical Journal Of The American Society Of Nephrology 2022, 17: 1555-1558. PMID: 35998975, PMCID: PMC9528262, DOI: 10.2215/cjn.05190422.Peer-Reviewed Original ResearchA Practical Guide to Genetic Testing for Kidney Disorders of Unknown Etiology
Aron AW, Dahl NK, Besse W. A Practical Guide to Genetic Testing for Kidney Disorders of Unknown Etiology. Kidney360 2022, 3: 1640-1651. PMID: 36245662, PMCID: PMC9528385, DOI: 10.34067/kid.0007552021.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsClinical genetic testingGenetic testingIdentification of pathogenic variantsLimitations of genetic testingKidney-related disordersOut-of-pocket costsRisks of testingVariant nomenclatureProvider educationPathogenic variantsGene panelPatient's desireDiagnosis of kidney diseaseProvidersFollow-up investigationKidney diseaseDiagnostic utilityDiagnostic limitationsKidney disordersValuable diagnostic toolUnknown etiologyGenetic risk allelesUndetermined causeGuide managementDiagnosis
2019
Risk factors and safe contrast volume thresholds for postcontrast acute kidney injury after peripheral vascular interventions
Lee SR, Zhuo H, Zhang Y, Dahl N, Dardik A, Ochoa Chaar CI. Risk factors and safe contrast volume thresholds for postcontrast acute kidney injury after peripheral vascular interventions. Journal Of Vascular Surgery 2019, 72: 603-610.e1. PMID: 31843298, DOI: 10.1016/j.jvs.2019.09.059.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAgedCanadaContrast MediaDatabases, FactualEndovascular ProceduresFemaleHumansIncidenceKidneyMaleMiddle AgedPatient SafetyPeripheral Arterial DiseaseRadiography, InterventionalRenal Insufficiency, ChronicRetrospective StudiesRisk AssessmentRisk FactorsTreatment OutcomeUnited StatesConceptsAdvanced chronic kidney diseaseChronic kidney diseasePeripheral vascular interventionsStages of CKDPostcontrast acute kidney injuryBaseline kidney functionPC-AKIAcute kidney injuryContrast volumeVolume of contrastRisk factorsKidney injuryCumulative incidenceLimb ischemiaKidney functionVascular interventionsMultivariable Cox proportional hazards regressionCox proportional hazards regressionAcute limb ischemiaLong-term mortalityCritical limb ischemiaNormal kidney functionMultivariable logistic regressionProportional hazards regressionLong-term survival
2018
Quantification of Urinary Protein Biomarkers of Autosomal Dominant Polycystic Kidney Disease by Parallel Reaction Monitoring
Rauniyar N, Yu X, Cantley J, Voss EZ, Belcher J, Colangelo CM, Stone KL, Dahl N, Parikh C, Lam TT, Cantley LG. Quantification of Urinary Protein Biomarkers of Autosomal Dominant Polycystic Kidney Disease by Parallel Reaction Monitoring. Proteomics Clinical Applications 2018, 12: e1700157. PMID: 29573172, PMCID: PMC6736530, DOI: 10.1002/prca.201700157.Peer-Reviewed Original ResearchConceptsAutosomal dominant polycystic kidney diseaseDominant polycystic kidney diseasePolycystic kidney diseaseCyst growthKidney diseaseUrinary proteinNormal controlsEnd-stage renal failureUrine samplesUrinary protein biomarkersLife-long diseasePresence of cystsRespective urine samplesMost patientsRenal failureADPKD patientsEarly diagnosisClinical relevanceUrinary proteomeParallel reaction monitoringPatientsCyst formationDiseaseWater intakePathogenesisSemaphorin 7A in circulating regulatory T cells is increased in autosomal-dominant polycystic kidney disease and decreases with tolvaptan treatment
Lee Y, Blount KL, Dai F, Thompson S, Scher JK, Bitterman S, Droher M, Herzog EL, Moeckel G, Karihaloo A, Dahl NK. Semaphorin 7A in circulating regulatory T cells is increased in autosomal-dominant polycystic kidney disease and decreases with tolvaptan treatment. Clinical And Experimental Nephrology 2018, 22: 906-916. PMID: 29453607, DOI: 10.1007/s10157-018-1542-x.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsAutosomal dominant polycystic kidney diseaseEnd-stage renal diseaseRenal fibrosisSEMA7A expressionADPKD patientsTolvaptan treatmentPolycystic kidney diseaseKidney diseaseNumber of PBMCsExpression of SEMA7ASubsequent renal fibrosisMarkers of inflammationRegulatory T cellsADPKD kidneysBlood mononuclear cellsImmunomodulating proteinsRenal diseaseMononuclear cellsSmall kidneysKidney fibrosisLiver fibrosisRenal cystsSemaphorin 7AT cells
2012
Evaluation of urine biomarkers of kidney injury in polycystic kidney disease
Parikh CR, Dahl NK, Chapman AB, Bost JE, Edelstein CL, Comer DM, Zeltner R, Tian X, Grantham JJ, Somlo S. Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney International 2012, 81: 784-790. PMID: 22258321, PMCID: PMC3319327, DOI: 10.1038/ki.2011.465.Peer-Reviewed Original ResearchMeSH KeywordsAcute-Phase ProteinsAdultAnimalsBiomarkersDisease ProgressionFemaleHumansInterleukin-18KidneyKidney Failure, ChronicLipocalin-2LipocalinsLongitudinal StudiesMaleMiceMice, KnockoutMice, TransgenicOncogene ProteinsPolycystic Kidney, Autosomal DominantProto-Oncogene ProteinsRatsRats, Mutant StrainsRats, Sprague-DawleyReceptors, Interleukin-18TRPP Cation ChannelsConceptsAutosomal dominant polycystic kidney diseaseTotal kidney volumeKidney volumeIL-18Polycystic kidney diseaseKidney diseaseCyst fluidRenal tubular integrityIL-18 levelsRenal Disease equationSerial urine samplesGlomerular filtration rateModification of DietExpression of Lcn2Min/yearPolycystic Kidney Disease (CRISP) studyUrine of patientsDominant polycystic kidney diseaseKidney Disease studyUrinary collecting systemMean percentage increaseSPRD rat modelUrinary NGALUrine NGALKidney injuryResolution of proteinuria in a patient with focal segmental glomerulosclerosis following BiPAP initiation for obesity hypoventilation syndrome.
Hall IE, Kashgarian M, Moeckel GW, Dahl NK. Resolution of proteinuria in a patient with focal segmental glomerulosclerosis following BiPAP initiation for obesity hypoventilation syndrome. Clinical Nephrology 2012, 77: 62-5. PMID: 22185970, DOI: 10.5414/cn106859.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaFocal segmental glomerulosclerosisSleep apneaSegmental glomerulosclerosisBi-level positive airway pressureSecondary focal segmental glomerulosclerosisObesity hypoventilation syndromePositive airway pressureResolution of proteinuriaPatient's proteinuriaGlomerular hyperfiltrationAirway pressureSevere obesityHypoventilation syndromeHeavy proteinuriaComplete resolutionProteinuriaGlomerulosclerosisApneaObesityPatientsTreatmentHyperfiltrationSyndrome
2008
Thrombotic Microangiopathy and Renal Failure Exacerbated by ε-Aminocaproic Acid
Mutter WP, Stillman IE, Dahl NK. Thrombotic Microangiopathy and Renal Failure Exacerbated by ε-Aminocaproic Acid. American Journal Of Kidney Diseases 2008, 53: 346-350. PMID: 18805613, DOI: 10.1053/j.ajkd.2008.07.023.Peer-Reviewed Original Research